The post-translational modification, SUMOylation, and cancer (Review)

International Journal of Oncology
Zhi-Jian HanHao Chen

Abstract

SUMOylation is a reversible post-translational modification which has emerged as a crucial molecular regulatory mechanism, involved in the regulation of DNA damage repair, immune responses, carcinogenesis, cell cycle progression and apoptosis. Four SUMO isoforms have been identified, which are SUMO1, SUMO2/3 and SUMO4. The small ubiquitin-like modifier (SUMO) pathway is conserved in all eukaryotes and plays pivotal roles in the regulation of gene expression, cellular signaling and the maintenance of genomic integrity. The SUMO catalytic cycle includes maturation, activation, conjugation, ligation and de-modification. The dysregulation of the SUMO system is associated with a number of diseases, particularly cancer. SUMOylation is widely involved in carcinogenesis, DNA damage response, cancer cell proliferation, metastasis and apoptosis. SUMO can be used as a potential therapeutic target for cancer. In this review, we briefly outline the basic concepts of the SUMO system and summarize the involvement of SUMO proteins in cancer cells in order to better understand the role of SUMO in human disease.

References

Apr 3, 1999·The Journal of Biological Chemistry·J M DesterroR T Hay
Feb 29, 2000·The Journal of Biological Chemistry·H Saitoh, J Hinchey
Jul 14, 2001·The Journal of Biological Chemistry·M H TathamR T Hay
Apr 8, 2003·Cell·Michael H KageyDavid Wotton
Sep 25, 2003·Nature Reviews. Molecular Cell Biology·Jacob-S Seeler, Anne Dejean
Nov 11, 2003·Trends in Biochemical Sciences·Frauke MelchiorAndrea Pichler
Mar 17, 2004·Oncogene·Stefan MüllerDarja Schmidt
Sep 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jing SongYuan Chen
Oct 29, 2004·Nature Reviews. Cancer·Ann M Bode, Zigang Dong
Dec 21, 2004·Nature Structural & Molecular Biology·Michael H TathamRonald T Hay
Feb 22, 2005·Nature Structural & Molecular Biology·Andrea PichlerTitia K Sixma
Mar 1, 2005·Oncogene·Yin-Yuan MoWilliam T Beck
Jun 3, 2005·Nature·David Reverter, Christopher D Lima
Oct 4, 2005·Biochemical and Biophysical Research Communications·David OwerbachKurt M Bohren
Mar 29, 2006·Experimental Cell Research·Zhaohui LuYin-Yuan Mo
Nov 18, 2006·Cell·Gaorav P Gupta, Joan Massagué
Nov 28, 2006·Biochimica Et Biophysica Acta·James A McCubreyRichard A Franklin
Dec 13, 2006·Nature Cell Biology·Shrikrishna DadkeJonathan Chernoff
Mar 21, 2007·Nature Cell Biology·Stephanie CarterKaren H Vousden
Aug 28, 2007·Current Opinion in Plant Biology·Kenji MiuraPaul M Hasegawa
Oct 13, 2007·The Journal of Biological Chemistry·Tasneem Bawa-KhalfeEdward T H Yeh
Dec 19, 2007·Molecular and Cellular Biology·Elaine M TaylorAlan R Lehmann
Apr 17, 2008·Journal of Cancer Research and Clinical Oncology·Karl-Hartmut von Wangenheim, Hans-Peter Peterson
Nov 15, 2008·The Journal of Biological Chemistry·Edward T H Yeh
Jan 24, 2009·Biochimica Et Biophysica Acta·Jung Hwa Kim, Sung Hee Baek
Feb 19, 2009·Biochemical and Biophysical Research Communications·Cong-Yi WangFeili Gong
Feb 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fangting WuYin-Yuan Mo
Mar 28, 2009·Nature·Steven Bergink, Stefan Jentsch
May 28, 2009·Science Signaling·Filip GolebiowskiRonald T Hay
Jun 16, 2009·Cellular and Molecular Life Sciences : CMLS·Miia M RytinkiJorma J Palvimo
Jul 21, 2009·Biochemical Society Transactions·Louise N Johnson
Nov 20, 2009·Journal of Cell Science·Yonggang Wang, Mary Dasso

❮ Previous
Next ❯

Citations

Dec 24, 2019·Frontiers in Bioengineering and Biotechnology·Wang-Ren QiuXuan Xiao
May 13, 2020·Cancers·Haiyoung JungHee Gu Lee
Jul 8, 2020·Biomedicines·Yue JiaSamuel W French
Aug 14, 2019·International Journal of Molecular Sciences·Mathias BoulangerGuillaume Bossis
Jun 18, 2020·International Journal of Molecular Sciences·Emmanuel AmpofoMatthias W Laschke
Apr 10, 2019·Neural Regeneration Research·Dian-Ying ZhangYan-Xia Li
Apr 17, 2020·Frontiers in Cell and Developmental Biology·Wenchen PuYong Peng
Feb 3, 2021·Cells·Graham Chakafana, Addmore Shonhai
Feb 7, 2021·International Journal of Molecular Sciences·Junyan QuZhenghong Lin
Jan 2, 2021·International Journal of Molecular Sciences·Adam AlbaneseViolaine Sée
Apr 4, 2021·International Journal of Molecular Sciences·Charlotte BussienneSerena Bernacchi
Jun 8, 2021·Frontiers in Oncology·Jianing Ding, Peng Kuang
Jun 29, 2021·Frontiers in Oncology·María Paz SaldíasOscar Cerda
Aug 4, 2021·Cancer Metastasis Reviews·Nianhong ChenPing Shi
Nov 21, 2020·ACS Medicinal Chemistry Letters·Christopher M BrackettBrian S J Blagg
Apr 1, 2020·Journal of Proteome Research·Clémence Rinfret RobertPierre Thibault
Aug 28, 2021·Experimental and Therapeutic Medicine·Juan LiuXiaozhi Liu
Dec 24, 2021·Journal of Chemical Information and Modeling·Gamze TanriverSaron Catak

❮ Previous
Next ❯

Methods Mentioned

BETA
protein modification
ubiquitination
acetylation
neddylation
deubiquitination
protein folding
ChIP-seq
affinity purification
xenograft
transfection

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

The FEBS Journal
Karolin Eifler, Alfred C O Vertegaal
Cancer Letters
Kira BettermannJohannes Haybaeck
Methods in Molecular Biology
Simona Citro, Susanna Chiocca
© 2022 Meta ULC. All rights reserved